17-hydroxyprogesterone ester containing oral compositions and related methods
The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.
1. An oral pharmaceutical composition, comprising: a therapeutically effective amount of 17-hydroxyprogesterone caproate having a mean particulate diameter of about 50 micron or less, and a pharmaceutically acceptable carrier including at least a hydrophilic surfactant; wherein the amount of the 17-hydroxyprogesterone caproate is from about 5% to about 80% w/w of the total composition; and wherein, when measured using a USP Type-II dissolution apparatus in 900 mL of simulated intestinal fluid having 0.5% w/w sodium lauryl sulfate at 50 RPM at 37° C., at least 20% of the 17-hydroxyprogesterone caproate is released from the oral composition at 60 minutes.
2. The oral pharmaceutical composition of claim 1 wherein said hydrophilic surfactant is an ionic hydrophilic surfactant.
3. The oral pharmaceutical composition of claim 1 wherein said hydrophilic surfactant is a non-ionic hydrophilic surfactant.
4. The oral pharmaceutical composition of claim 1 wherein said hydrophilic surfactant is a poloxamer, a polyethylene glycol sorbitan fatty acid ester, a sorbitan fatty acid ester, a polyethylene glycol glycerol fatty acid ester or a combination thereof.
5. The oral pharmaceutical composition of claim 1 wherein said hydrophilic surfactant is sodium lauryl sulfate, sodium dioctyl sulfosuccinate, a lecithin, a bile salt or a combination thereof.
6. The oral pharmaceutical composition of claim 1 further comprising polyvinylpyrrolidone, croscarmellose, microcrystalline cellulose, magnesium stearate, silicon dioxide, stearic acid, mannitol, a polyvinyl alcohol copolymer, a polyvinylpyrrolidone copolymer, a polyethylene glycol copolymer, a methacrylic acid copolymer, or a combination thereof.
7. The oral pharmaceutical composition of claim 1 formulated as a powder, granulate, particulate, bead, pellet, sprinkle, suspension, solution, tablet, capsule, or a combination thereof.
8. The oral pharmaceutical composition of claim 1 formulated as a capsule.
9. The oral pharmaceutical composition of claim 1 formulated as a tablet.
10. The oral pharmaceutical composition having an amount of 17-hydroxyprogesterone caproate equivalent to from about 20 mg to about 400 mg of 17-hydroxyprogesterone.
11. The oral pharmaceutical composition of claim 1 having from about 20 mg to about 800 mg 17-hydroxyprogesterone caproate.
12. The oral pharmaceutical composition of claim 1 having from about 10 mg to about 300 mg 17-hydroxyprogesterone caproate.
13. An oral pharmaceutical composition, comprising: a therapeutically effective amount of 17-hydroxyprogesterone caproate having a mean particulate diameter of about 50 micron or less, and a pharmaceutically acceptable carrier including at least an ionic hydrophilic surfactant; wherein the amount of the 17-hydroxyprogesterone caproate is from about 5% to about 80% w/w of the total composition; and wherein, when measured using a USP Type-II dissolution apparatus in 900 mL of simulated intestinal fluid having 0.5% w/w sodium lauryl sulfate at 50 RPM at 37° C., at least 20% of the 17-hydroxyprogesterone caproate is released from the oral composition at 60 minutes.
14. The oral pharmaceutical composition of claim 13 further comprising polyvinylpyrrolidone, croscarmellose, microcrystalline cellulose, magnesium stearate, silicon dioxide, stearic acid, mannitol, a polyvinyl alcohol copolymer, a polyvinylpyrrolidone copolymer, a polyethylene glycol copolymer, a methacrylic acid copolymer, or a combination thereof.
15. The oral pharmaceutical composition of claim 13 wherein said hydrophilic surfactant is sodium lauryl sulfate, sodium dioctyl sulfosuccinate, a lecithin, a bile salt or a combination thereof.
16. The oral pharmaceutical composition of claim 13 formulated as a powder, granulate, particulate, bead, pellet, sprinkle, suspension, solution, tablet, capsule, or a combination thereof.
17. The oral pharmaceutical composition of claim 13 formulated as a capsule.
18. The oral pharmaceutical composition of claim 13 formulated as a tablet.
19. The oral pharmaceutical composition of claim 13 having an amount of 17-hydroxyprogesterone caproate equivalent to from about 10 mg to about 800 mg of 17-hydroxyprogesterone.
20. An oral pharmaceutical composition, comprising: a therapeutically effective amount of 17-hydroxyprogesterone caproate having a mean particulate diameter of about 50 micron or less, and a pharmaceutically acceptable carrier including at least a non-ionic hydrophilic surfactant; wherein the amount of the 17-hydroxyprogesterone caproate is from about 5% to about 80% w/w of the total composition; and wherein, when measured using a USP Type-II dissolution apparatus in 900 mL of simulated intestinal fluid having 0.5% w/w sodium lauryl sulfate at 50 RPM at 37° C., at least 20% of the 17-hydroxyprogesterone caproate is released from the oral composition at 60 minutes.
21. The oral pharmaceutical composition of claim 20 further comprising polyvinylpyrrolidone, croscarmellose, microcrystalline cellulose, magnesium stearate, silicon dioxide, stearic acid, mannitol, a polyvinyl alcohol copolymer, a polyvinylpyrrolidone copolymer, a polyethylene glycol copolymer, a methacrylic acid copolymer, or a combination thereof.
22. The oral pharmaceutical composition of claim 20 wherein said hydrophilic surfactant is a poloxamer, a polyethylene glycol sorbitan fatty acid ester, a sorbitan fatty acid ester, a polyethylene glycol glycerol fatty acid ester or a combination thereof.
23. The oral pharmaceutical composition of claim 20 formulated as a powder, granulate, particulate, bead, pellet, sprinkle, suspension, solution, tablet, capsule, or a combination thereof.
24. The oral pharmaceutical composition of claim 20 formulated as a capsule.
25. The oral pharmaceutical composition of claim 20 formulated as a tablet.
26. The oral pharmaceutical composition of claim 20 having an amount of 17-hydroxyprogesterone caproate equivalent to from about 10 mg to about 800 mg of 17-hydroxyprogesterone.
27. An oral pharmaceutical composition, comprising: a therapeutically effective amount of 17-hydroxyprogesterone caproate having a mean particulate diameter of about 50 micron or less, and a pharmaceutically acceptable carrier including at least a hydrophilic surfactant chosen from a poloxamer, a polyethylene glycol sorbitan fatty acid ester, a sorbitan fatty acid ester, a polyethylene glycol glycerol fatty acid ester, sodium lauryl sulfate, sodium dioctyl sulfosuccinate, a lecithin, a bile salt or a combination thereof and said pharmaceutically acceptable carrier further comprising polyvinylpyrrolidone, croscarmellose, microcrystalline cellulose, magnesium stearate, silicon dioxide, stearic acid, mannitol, a polyvinyl alcohol copolymer, a polyvinylpyrrolidone copolymer, a polyethylene glycol copolymer, a methacrylic acid copolymer or a combination thereof wherein the amount of the 17-hydroxyprogesterone caproate is from about 5% to about 80% w/w of the total composition; and wherein, when measured using a USP Type-II dissolution apparatus in 900 mL of simulated intestinal fluid having 0.5% w/w sodium lauryl sulfate at 50 RPM at 37° C., at least 20% of the 17-hydroxyprogesterone caproate is released from the oral composition at 60 minutes.
28. The oral pharmaceutical composition of claim 27 formulated as a powder, granulate, particulate, bead, pellet, sprinkle, suspension, solution, tablet, capsule, or a combination thereof.
29. The oral pharmaceutical composition of claim 27 formulated as a capsule.
30. The oral pharmaceutical composition of claim 27 formulated as a tablet.
31. The oral pharmaceutical composition of claim 27 having an amount of 17-hydroxyprogesterone caproate equivalent to from about 10 mg to about 800 mg of 17-hydroxyprogesterone.
32. The oral pharmaceutical composition of claim 27 having an amount of 17-hydroxyprogesterone caproate equivalent to from about 20 mg to about 400 mg of 17-hydroxyprogesterone.
33. The oral pharmaceutical composition of claim 27 having from about 10 mg to about 300 mg 17-hydroxyprogesterone caproate.